ItMSCs: Phase IIa started

Stemedica’s CardioCell LLC subsidiary began a single-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate a single dose of 1.5 million cells/kg IV itMSCs in about 20 CHF patients wit...